While TPO-RAs are FDA-approved for conditions such as immune thrombocytopenia (ITP), hepatitis C-associated thrombocytopenia, aplastic anemia, and periprocedural thrombocytopenia in chronic liver disease, their role in CIT remains under investigation. Here, TPO is linked to idiopathic aplastic anemia.